Haematology-Oncology · Clinical trials
Myelodysplastic Syndromes (MDS) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About myelodysplastic syndromes (mds) — and why its trials are hard
Myelodysplastic syndromes are a group of clonal bone-marrow disorders marked by ineffective blood-cell production, cytopenias, and a risk of progression to acute myeloid leukemia. Management is risk-adapted using the IPSS-R and molecular IPSS-M scores. Lower-risk disease focuses on improving cytopenias and quality of life: erythropoiesis-stimulating agents, the erythroid maturation agent luspatercept for anemia (especially with ring sideroblasts), and lenalidomide for del(5q) syndrome. Higher-risk disease is treated with hypomethylating agents azacitidine or decitabine, which can delay AML progression and, for azacitidine, prolong survival; allogeneic stem-cell transplant remains the only curative option. Targeted therapy has entered the field with the IDH1 inhibitor ivosidenib for relapsed/refractory IDH1-mutated MDS. Transfusion dependence, iron overload, and infection risk drive supportive-care needs. Despite decades of combination trials, few agents added to hypomethylating backbones have improved outcomes, underscoring the biological complexity and heterogeneity of the disease.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Azacitidine (Vidaza) | 2004 | Higher-risk MDS | AZA-001 (CALGB 9221) | Overall survival | Median OS 24.5 vs 15 months vs conventional care (AZA-001) |
| Lenalidomide (Revlimid) | 2005 | Lower-risk MDS with del(5q) and transfusion-dependent anemia | MDS-003 | Transfusion independence | ~67% achieved RBC transfusion independence; ~73% cytogenetic response |
| Decitabine (Dacogen) | 2006 | Intermediate/higher-risk MDS | D-0007 | Overall response rate | Improved response and delayed AML transformation vs supportive care |
| Luspatercept (Reblozyl) | 2020 | Lower-risk MDS with ring sideroblasts, transfusion-dependent anemia (later first-line ESA-naive) | MEDALIST (first-line: COMMANDS) | RBC transfusion independence | RBC-TI >=8 weeks in ~38% vs ~13% placebo (MEDALIST); superior to epoetin alfa in COMMANDS |
| Ivosidenib (Tibsovo) | 2023 | R/R MDS with an IDH1 mutation | Phase 1 (AG120-C-001) | Complete remission / transfusion independence | High CR rate and durable transfusion independence in IDH1-mutant R/R MDS |
| Decitabine + cedazuridine (oral) (Inqovi) | 2020 | Intermediate/higher-risk MDS (oral hypomethylating) | ASCERTAIN | Pharmacokinetic equivalence / response | Oral exposure equivalent to IV decitabine, enabling all-oral dosing |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in myelodysplastic syndromes (mds) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rigosertib — ONTIME (and INSPIRE) | Failed to significantly improve overall survival in higher-risk MDS after hypomethylating-agent failure | No OS benefit in the overall population; subgroup signals not confirmed in the subsequent INSPIRE trial |
| Pevonedistat (+ azacitidine) — PANTHER | Did not meet primary event-free survival endpoint vs azacitidine alone | Combination added no significant benefit over hypomethylating monotherapy in higher-risk MDS/AML |
| Sabatolimab (anti-TIM-3, + azacitidine) — STIMULUS-MDS2 | Failed to significantly improve overall survival in higher-risk MDS | Immune-targeting combination did not translate into a survival advantage over azacitidine |
Choosing the right endpoint
Primary endpoints that matter in myelodysplastic syndromes (mds) trials
- Overall survival (OS) — Key endpoint in higher-risk disease; azacitidine (AZA-001) demonstrated an OS benefit
- RBC transfusion independence (RBC-TI) — Primary endpoint in lower-risk anemia trials (MEDALIST, COMMANDS)
- Hematologic improvement (HI) — IWG-defined erythroid/platelet/neutrophil response used across lower-risk trials
- Complete remission (CR) rate — Relevant for hypomethylating agents and targeted therapy (ivosidenib)
- Time to AML transformation — Captures disease-modifying effect and delay of leukemic progression
How iNGENū runs myelodysplastic syndromes (mds) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Myelodysplastic Syndromes (MDS) clinical trials — FAQs
How is MDS risk assessed?
What is luspatercept used for in MDS?
Can MDS be cured?
Ready to discuss your myelodysplastic syndromes (mds) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal